25.02.2019 23:55:53

Press Release: Novartis issues summary financial -2-

potential significant breaches of data security or data privacy, or

disruptions of our information technology systems or those of Alcon as a

standalone company; and other risks and factors referred to in Novartis

AG's current Form 20-F on file with the U.S. Securities and Exchange

Commission (SEC) or in the initial Form 20-F filed by Alcon with the

SEC. Novartis is providing the information in this press release as of

this date and does not undertake any obligation to update any

forward-looking statements as a result of new information, future events

or otherwise.

This press release is not an offer to sell, or a solicitation of an

offer to buy or sell, any securities of Novartis or, following the

proposed spinoff, of Alcon, and may not be relied upon in connection

with the purchase or sale of any such security. Should you wish to

invest in Alcon, you should do so solely on the basis of information

Alcon will file with the SEC at or around the time of the spinoff,

including the section "Risk Factors" included in the Form 20-F. The

information filed with the SEC will be available on the SEC's website at

www.sec.gov.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 800 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 130,000 people of more than 145 nationalities

work at Novartis around the world. To learn more, visit

www.novartis.com.

About Alcon

Alcon is the global leader in eye care devices. As a division of

Novartis, we offer the broadest portfolio of products to enhance sight

and improve people's lives. Our products touch the lives of more than

260 million people each year living with conditions like cataracts,

glaucoma, retinal diseases and refractive errors, and there are millions

more who are waiting for solutions to meet their eye care needs. Our

purpose is reimagining eye care, and we do this through innovative

products, partnerships with eye care professionals and programs that

enhance access to quality eye care. Learn more at www.alcon.com (link is

external).

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Paul Barrett Wes Warnock

Novartis Group Communications Alcon Global External Communications

+41 61 324 5224 (direct) +1 817 615 2501 (direct)

+41 79 797 8137 (mobile) +1 210 240 4998 (mobile)

paul.barett@novartis.com wes.warnock@alcon.com

Eric Althoff

Novartis Global Media Relations

+41 61 324 7999 (direct)

+41 79 593 4202 (mobile)

eric.althoff@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2236409/880733.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

February 25, 2019 17:55 ET (22:55 GMT)

Analysen zu Novartis AGmehr Analysen

25.11.24 Novartis Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
22.11.24 Novartis Hold Deutsche Bank AG
22.11.24 Novartis Neutral Goldman Sachs Group Inc.
21.11.24 Novartis Neutral Goldman Sachs Group Inc.
21.11.24 Novartis Underweight Barclays Capital
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Novartis AG 80,10 -0,27% Novartis AG
Novartis AG (Spons. ADRS) 98,60 0,00% Novartis AG (Spons. ADRS)